drug

TAK-041

MeSH C000721087
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Neurocrine Biosciences
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
NCT02748694Phase 1Completed
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
NCT03319953Phase 2Completed

KOLs & investigators

1
Medical Director Clinical Science

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Neurocrine Biosciences
company
trial
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
PHASE1
trial
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Healthy Volunteers
indication
Stable Schizophrenia
indication
KOL
Medical Director Clinical Science
KOL score —
person